Non-consolidated Financial Results for the Fiscal Year Ended August 31, 2026 [Japanese GAAP]
Filed with TSE · · 14 pages · English
Summary by 6ix AI
The report indicates that the company experienced an operating loss and a net loss for the period, with no business revenue reported. Additionally, the financial position shows a decline in total assets and net assets compared to the previous fiscal year. The company has not provided a financial forecast for the upcoming fiscal year due to uncertainties in estimating results.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Chordia Therapeutics Inc. on 6ix
In the deck
Story so far
Earlier from Chordia Therapeutics
- Announcement Regarding AMED Grant Award for rogocekib (CTX-712)
- Announcement Regarding Completion of Patient Enrollment in the Initial Expansion Cohort of rogocekib
- Announcement of Orphan Drug Designation in Japan for rogocekib for Relapsed or Refractory AML
- Announcement Regarding the Review Status of Orphan Drug Designation for Rogocekib, a CLK Inhibitor
- Notice of Receipt of Grant
Later from Chordia Therapeutics
- Fiscal year ended August 2026 Financial Results Presentation
- Announcement Regarding the Reduction of Capital Reserve and Appropriation of Surplus
Follow Chordia Therapeutics into a list and get an email when it puts out news.
Follow Chordia Therapeutics